Filing Analysis
Korro Bio, Inc. announced the submission of a clinical trial application to the Alfred Health Human Ethics Committee to initiate a Phase 1/2 clinical trial for its RNA editing candidate, KRRO-121. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of the treatment for hyperammonemia in patients with Urea Cycle Disorders (UCDs).
📋 Key Facts
- Submission made to the Australian Alfred Health Human Ethics Committee.
- Targeting a first-in-human Phase 1/2 clinical trial for KRRO-121.
- KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide.
- Indication: Hyperammonemia in patients with Urea Cycle Disorders (UCDs).
- Trial objectives: Safety, tolerability, pharmacokinetics, and efficacy in healthy volunteers and UCD patients.
- ClinicalTrials.gov identifier: NCT 07773246.
Korro Bio entered into an exchange agreement with Venrock Healthcare Capital Partners to surrender 1,000,000 common shares in exchange for pre-funded warrants to purchase 1,000,000 shares at a nominal price of $0.001 per share.
🚩 Red Flags
- Significant dilution potential: The exchange effectively converts existing equity into warrants that can be exercised at a near-zero price ($0.001).
- Concentrated ownership/Control: Warrants include a 9.99% beneficial ownership cap, indicating structured institutional positioning.
📋 Key Facts
- Venrock surrendered 1,000,000 common shares for no consideration on August 5, 2026.
- Korro issued pre-funded warrants to Venrock for 1,000,000 shares at an exercise price of $0.001 per share.
- Warrants have no expiration date and are exercisable immediately.
- Post-exchange capital structure: 13,725,646 shares outstanding and 4,148,836 unexercised pre-funded warrants.
- Issuance relied on Section 3(a)(9) of the Securities Act (exchange of previously issued securities).
Korro Bio, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. The stockholders elected two Class I directors, approved executive compensation in a non-binding vote, and ratified the appointment of Ernst & Young LLP as the independent auditor.
🚩 Red Flags
- The CEO is currently serving as the Interim CFO, which may indicate a vacancy in a key financial leadership role.
📋 Key Facts
- Nessan Bermingham and Rachel Meyers were elected as Class I directors for three-year terms ending in 2029.
- Executive compensation was approved via a non-binding advisory vote with 9,009,739 votes 'For' and 27,988 votes 'Against'.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 10,917,621 votes 'For'.
- The filing was signed by Ram Aiyar, who serves as President, CEO, and Interim CFO.
Korro Bio, Inc. announced the addition of KRRO-111, a new therapeutic candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD), to its development pipeline. The company also updated its corporate presentation slides for upcoming investor and analyst meetings.
📋 Key Facts
- Announced the addition of KRRO-111 to its therapeutic pipeline on May 19, 2026.
- KRRO-111 is being developed for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD).
- Updated corporate presentation slides were filed as Exhibit 99.2 for use in investor and analyst meetings.
- The report was filed under Item 8.01 (Other Events) and signed by Ram Aiyar, President, CEO, and Interim CFO.
Korro Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as Exhibit 99.1.
🚩 Red Flags
- The CEO (Ram Aiyar) is also serving as the Interim CFO, indicating a vacancy in a key executive financial position.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 7, 2026.
- Ram Aiyar is currently serving as President, Chief Executive Officer, and Interim Chief Financial Officer.
Korro Bio, Inc. announced its financial results for the fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the filing.
🚩 Red Flags
- CEO Ram Aiyar is also serving as Interim CFO, indicating a lack of a dedicated permanent Chief Financial Officer.
📋 Key Facts
- Financial results reported for the full year ended December 31, 2025
- Report filed on March 12, 2026
- Ram Aiyar is currently serving as President, CEO, and Interim Chief Financial Officer
- Information furnished under Item 2.02 is not deemed 'filed' for Section 18 liability purposes
Korro Bio, Inc. entered into a subscription agreement for a private placement (PIPE) to raise approximately $85.0 million in gross proceeds through the sale of common stock and pre-funded warrants. The financing, led by Venrock Healthcare Capital Partners, is expected to extend the company's cash runway into the second half of 2028.
🚩 Red Flags
- The CEO is currently serving as the Interim CFO, indicating a vacancy in a key executive position.
- The registration rights agreement includes liquidated damages provisions if deadlines for filing or effectiveness are not met.
- The offering is a private placement (PIPE), which is typically dilutive to existing shareholders.
📋 Key Facts
- Agreement to sell 4,501,928 shares of common stock at $11.11 per share.
- Agreement to sell 3,148,836 pre-funded warrants at $11.109 per warrant with an exercise price of $0.001.
- Gross proceeds of approximately $85.0 million before commissions and expenses.
- Participation from institutional investors including Venrock, ADAR1 Capital Management, Balyasny Asset Management, and New Enterprise Associates.
- Preliminary cash, cash equivalents, and marketable securities of $85.2 million as of December 31, 2025.
- Company must file a resale registration statement within 30 days of closing and cause it to be effective within 60-90 days.
- Ram Aiyar is currently serving as both President/CEO and Interim Chief Financial Officer.
Korro Bio, Inc. held a virtual Analyst Day on January 27, 2026, providing updated presentation materials to investors.
📋 Key Facts
- Event: Virtual Analyst Day hosted by Korro Bio, Inc.
- Date of Event: January 27, 2026
- Exhibits: Presentation slides from the event were filed as Exhibit 99.1.
Korro Bio, Inc. filed an 8-K to announce the update of its corporate presentation for use in meetings with investors and analysts.
📋 Key Facts
- The company updated its corporate presentation on January 15, 2026.
- The updated slides are provided as Exhibit 99.1.
- Ram Aiyar signed the filing as President, CEO, and Interim CFO.
Korro Bio, Inc. has entered into an amended and restated employment agreement with Jeffrey Cerio, effective December 15, 2025. The amendment primarily adjusts his compensation structure to reflect current salary levels and enhances severance terms.
🚩 Red Flags
- Increased severance packages can be viewed as a defensive measure for management but generally represent an increased liability for the company.
📋 Key Facts
- Effective date of amendment: December 15, 2025.
- Annual base salary increased to $425,000.
- Severance for termination without cause/resignation for good reason increased from 6 to 9 months (standard) and 9 to 12 months (during change in control period).
- Awarded a $100,000 cash bonus: 50% due Dec 31, 2025; 50% due ~June 30, 2026.
- Granted 41,902 Restricted Stock Units (RSUs) vesting in two tranches: 50% on June 15, 2026, and 50% on December 15, 2026.
Korro Bio is undergoing significant restructuring, including a 34% workforce reduction and the suspension of its major research collaboration with Novo Nordisk for 12 months. The company is implementing these measures to extend its cash runway following disappointing or stalled development progress.
🚩 Red Flags
- Suspension of a major material collaboration with Novo Nordisk for 12 months.
- Significant workforce reduction (34%) indicating severe cash runway concerns.
- Departure of the Chief Medical Officer (CMO) amidst restructuring.
- Multiple negative events in a single filing: agreement suspension, layoffs, and executive departure.
📋 Key Facts
- Effective November 11, 2025, Korro Bio and Novo Nordisk amended their research collaboration/license agreement to a 12-month 'hold period'.
- During the hold period, all R&D activities and payment obligations under the Novo Nordisk agreement are suspended.
- Korro is implementing a strategic restructuring involving a workforce reduction of approximately 34%.
- The company expects to incur approximately $2.4 million in one-time restructuring charges (severance/benefits) primarily in Q4 2025.
- Chief Medical Officer Dr. Olukemi A. Olugemo resigned effective November 12, 2025, to pursue other opportunities.
Korro Bio, Inc. announced the resignation of CFO Vineet Agarwal, effective October 17, 2025. The CEO, Dr. Ram Aiyar, will assume the role of interim CFO and principal financial officer.
🚩 Red Flags
- Sudden departure of a key C-suite officer (CFO) in a micro-cap biotech environment.
- CEO taking on the dual role of CEO and interim CFO, which can create significant administrative burden and distraction from core operations.
📋 Key Facts
- Vineet Agarwal is resigning as CFO on October 17, 2025, to pursue other opportunities.
- The departure is not related to any disagreements regarding management or operations.
- Dr. Ram Aiyar (CEO) will serve as interim CFO and principal financial officer effective October 17, 2025.
- Mr. Agarwal will serve as an advisor for 30 days following his resignation to ensure a smooth transition.
- Korro Bio extended the post-termination exercise period for Mr. Agarwal's vested stock options through March 31, 2027.
Korro Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal mechanism to furnish the earnings press release to the SEC.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) containing financial results.
- The filing is pursuant to Item 2.02 regarding Results of Operations and Financial Condition.
Korro Bio, Inc. filed an amendment to its 8-K to disclose the Board of Directors' decision regarding stockholder voting results from the 2025 Annual Meeting. The stockholders approved a '1 Year' frequency for future non-binding advisory votes on executive compensation.
📋 Key Facts
- The filing is an amendment (8-K/A) to the original 8-K filed on June 11, 2025.
- Stockholders voted at the 2025 Annual Meeting held on June 11, 2025.
- The advisory resolution for the frequency of future 'Say-on-Pay' votes was approved under the '1 Year' option.
- The Board determined that advisory votes on executive compensation will be held annually until at least the 2031 annual meeting.
Korro Bio, Inc. reported the results of its 2025 annual meeting of stockholders held on June 11, 2025. The meeting included elections for Class III directors and advisory votes regarding executive compensation and voting frequency.
📋 Key Facts
- Elected Ram Aiyar, Jean-François Formela, and Katharine Knobil as Class III directors for three-year terms ending in 2028.
- Stockholders approved the non-binding 'Say-on-Pay' advisory vote regarding executive compensation (7,972,389 votes 'For').
- Stockholders approved a 1-year frequency for future advisory votes on executive compensation.
- Ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Korro Bio, Inc. announced a strategic restructuring plan involving a 20% workforce reduction to streamline operations. The company expects to incur approximately $1.2 million in one-time restructuring charges, primarily recognized in the second quarter of 2025.
🚩 Red Flags
- Significant workforce reduction (20%) often indicates a need to preserve cash runway in pre-revenue biotech firms.
- One-time restructuring charges indicate immediate impact on upcoming quarterly earnings.
📋 Key Facts
- Initiated a strategic plan to streamline operations on May 7, 2025.
- Workforce reduction of approximately 20% of total employees.
- Estimated one-time restructuring charges of approximately $1.2 million.
- Restructuring costs include employee severance, benefits, and related termination costs.
- Majority of charges expected to be recognized in the quarter ended June 30, 2025.
- Simultaneous announcement of financial results for the quarter ended March 31, 2025.
Korro Bio, Inc. announced the return of Vineet Agarwal from a temporary medical leave of absence to his role as Chief Financial Officer, effective March 27, 2025. Consequently, Dr. Ram Aiyar steps down from his interim CFO duties, and Oliver Dolan is appointed as Principal Accounting Officer.
🚩 Red Flags
- The company experienced a sudden departure of its CFO due to medical leave starting February 11, 2025, indicating recent management instability.
📋 Key Facts
- Vineet Agarwal returned from medical leave on March 27, 2025, resuming duties as Chief Financial Officer.
- Dr. Ram Aiyar ceased serving as interim principal financial officer effective March 27, 2025.
- Oliver Dolan (SVP, Finance) appointed as Principal Accounting Officer, effective March 27, 2025.
- Mr. Dolan was granted a stock option to purchase 20,000 shares of common stock with an exercise price equal to the closing price on the grant date; effective April 1, 2025.
- No additional compensation was provided for Mr. Agarwal's reappointment.
Korro Bio, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal mechanism to furnish the annual press release via Exhibit 99.1.
📋 Key Facts
- Report date: March 18, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Company is listed on the Nasdaq Capital Market under ticker KRRO.
Korro Bio, Inc. announced that CFO Vineet Agarwal is taking a temporary medical leave of absence effective February 11, 2025. The company has appointed its CEO as interim PFO/PAO and the SVP of Finance as interim PAO to ensure continuity.
🚩 Red Flags
- Sudden departure of the CFO/Principal Financial Officer due to medical reasons creates temporary leadership vacuum in finance functions.
📋 Key Facts
- Vineet Agarwal (CFO, PFO, and PAO) is on temporary medical leave effective February 11, 2025.
- Dr. Ram Aiyar (CEO) appointed as interim Principal Financial Officer (PFO).
- Mr. Oliver Dolan (SVP, Finance) appointed as interim Principal Accounting Officer (PAO).
- Dr. Aiyar will receive no additional compensation for this interim role.
- Oliver Dolan has entered into a standard indemnification agreement.
Korro Bio, Inc. announced the dosing of the first participants in its REWRITE Phase 1/2a clinical study for KRRO-110 (Alpha-1 Antitrypsin Deficiency) and provided a pipeline update alongside an updated corporate presentation.
📋 Key Facts
- First participants dosed in REWRITE Phase 1/2a clinical study of KRRO-110 on January 13, 2025.
- KRRO-110 is targeting Alpha-1 Antitrypsin Deficiency.
- Company provided a pipeline update and updated its corporate presentation for investor use.
Korro Bio, Inc. announced regulatory clearance in Australia to initiate a first-in-human Phase 1/2a clinical study for its candidate KRRO-110, targeting Alpha-1 Antitrypsin Deficiency.
📋 Key Facts
- Received approval from the Australian Bellberry Human Research Ethics Committee on November 21, 2024.
- Received Clinical Trial Notification clearance from the Australian Therapeutic Goods Administration (TGA).
- The study is a first-in-human Phase 1/2a clinical trial for KRRO-110.
- Target indication: Alpha-1 Antitrypsin Deficiency.
Korro Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2024.
📋 Key Facts
- The filing is a routine announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the quarter ended September 30, 2024.
- The company is an emerging growth company as defined by Rule 405 of the Securities Act.
Korro Bio, Inc. filed an 8-K to announce the first regulatory filing for its KRRO-110 program via a press release.
📋 Key Facts
- The company announced its first regulatory filing for KRRO-110 on November 4, 2024.
- The announcement was made through a press release incorporated by reference as Exhibit 99.1.
- The filing is categorized under Item 8.01 (Other Events).
Korro Bio entered into a significant research collaboration and license agreement with Novo Nordisk, granting an exclusive worldwide license for certain intellectual property in the cardiometabolic field. The deal includes potential milestone payments totaling up to $530 million plus royalties.
🚩 Red Flags
- Novo Nordisk retains the right to terminate the agreement without cause on a per research program or per licensed product basis.
📋 Key Facts
- Entered into a research collaboration and license agreement with Novo Nordisk A/S on September 13, 2024.
- Potential total compensation of $530.0 million in milestone payments for two programs.
- Upfront fee of $10.0 million received for the initial cardiometabolic research program.
- Agreement includes tiered royalties at mid-single digit percentages of annual net sales.
- Korro Bio is responsible for R&D activities and is eligible for cost reimbursement from Novo Nordisk.
- The agreement covers an initial target in the cardiometabolic field and a second target to be nominated by Novo Nordisk.
Korro Bio, Inc. announced the resignation of Board member David L. Lucchino effective August 26, 2024, and the appointment of Katharine Knobil, M.D. to the Board and Compensation Committee.
🚩 Red Flags
- None identified; departure was stated as non-dispute related.
📋 Key Facts
- David L. Lucchino resigned from the Board on August 26, 2024; he stated his departure was not due to any disagreement with management or operations.
- The company entered into a consulting agreement with Mr. Lucchino for strategic advisory services through at least October 1, 2027.
- Consulting compensation includes $9,000/quarter until the 2026 annual meeting, then $2,000/quarter until the 2027 annual meeting, plus a $150,000 value option grant vesting in 2026.
- Katharine Knobil, M.D. appointed to the Board (Class III) and the Compensation Committee effective August 26, 2024.
- The Board restructured its size from seven to six directors and back to seven to facilitate Dr. Knobil's appointment.
Korro Bio, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2024. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- Company is an emerging growth company
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Korro Bio, Inc. announced that its Chief Scientific Officer, Steve Colletti, Ph.D., has submitted his resignation, effective August 2, 2024.
🚩 Red Flags
- Departure of a key scientific officer in a biotechnology company can signal internal shifts or challenges in the R&D pipeline.
📋 Key Facts
- Steve Colletti, Ph.D. is resigning from the position of Chief Scientific Officer.
- The resignation was notified on June 17, 2024.
- The effective date of departure is August 2, 2024.
Korro Bio, Inc. reported the results of its 2024 annual meeting of stockholders held on June 11, 2024. The meeting included the election of two class II directors and approval of charter amendments regarding officer liability.
📋 Key Facts
- Stockholders elected Ali Behbahani and Timothy Pearson as class II directors for three-year terms ending in 2027.
- Stockholders approved an amendment to the Restated Certificate of Incorporation to limit the liability of certain officers under Delaware law.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Korro Bio, Inc. announced the appointment of Dr. Kemi Olugemo as its new Chief Medical Officer, effective May 13, 2024.
📋 Key Facts
- Dr. Kemi Olugemo joined Korro Bio as Chief Medical Officer on May 13, 2024.
- Dr. Olugemo previously served as VP of Global Clinical Development at Ultragenyx Pharmaceutical Inc. (RARE).
- Her professional background includes leadership roles at Laronde, Inc., Ionis Pharmaceuticals (IONS), and Parexel International Corp.
- She has extensive experience in clinical development for rare and common diseases across multiple therapeutic areas.
Korro Bio, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024. The filing primarily serves as a vehicle to incorporate the press release containing these results by reference.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes Exhibit 99.1 (Press Release) containing financial results
- Company is classified as an 'emerging growth company'
Korro Bio, Inc. has successfully closed a private placement of common stock totaling approximately $70 million. The offering was led by Deep Track Capital and includes several prominent healthcare investors.
📋 Key Facts
- Closed a private placement on April 22, 2024.
- Issued 1,249,283 shares of common stock at $56.00 per share.
- Total aggregate purchase price: approximately $70 million.
- Led by Deep Track Capital; participants include Atlas Venture, Blue Owl Capital, NEA, Rock Springs Capital, and Tri Locum Partners.
- Company had $166.4 million in cash/equivalents as of Dec 31, 2023.
- Proceeds intended for Phase 1/2 trial of KRRO-110 (Alpha-1 Antitrypsin Deficiency) expected in 2026 and pipeline development.
Korro Bio, Inc. entered into a subscription agreement for a private placement of 1,249,283 shares at $56.00 per share, expected to raise approximately $70 million in gross proceeds. The funds are intended to support clinical trials and pipeline development through 2026.
🚩 Red Flags
- Registration rights agreement included, which may lead to future dilution upon the effectiveness of the resale registration statement.
📋 Key Facts
- Private placement of 1,249,283 shares of common stock at $56.00 per share.
- Total expected gross proceeds: approximately $70 million.
- Lead investor/participant: Deep Track Capital; other participants include Atlas Venture, Blue Owl Healthcare Opportunities, NEA, and Rock Springs Capital.
- Expected closing date: April 22, 2024.
- Proceeds to fund Phase 1/2 trial of KRRO-110 in Alpha-1 Antitrypsin Deficiency (anticipated 2026) and other pipeline programs.
- Company had $166.4 million in cash and equivalents as of December 31, 2023.
Korro Bio, Inc. filed an 8-K to furnish its year-end financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 26, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing the company's financial results.
- Company is classified as an 'Emerging Growth Company'.
Korro Bio, Inc. filed an 8-K to update its corporate presentation for investor and analyst meetings.
📋 Key Facts
- The filing was made on January 9, 2024.
- The company updated its corporate presentation (Exhibit 99.1) for use in meetings with investors, analysts, and others.